GRAIL, Inc. (GRAL) Wins Favorable FDA Panel Vote on Galleri PMA

An FDA advisory committee voted that benefits of GRAIL’s Galleri multi-cancer early detection test outweigh risks and supported its safety and effectiveness. FDA will make the final PMA decision in the coming months.Material DetailsContext by AI AnalystThis is a mid-stage regulatory milestone follo…